{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:46:55Z","timestamp":1793774815639,"version":"4.6.1"},"reference-count":47,"publisher":"The Journal of Rheumatology","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Eosinophilic granulomatosis with polyangiitis (EGPA) is characterized by frequent relapses following induction therapy. Interferon-\u03b1 (IFN-\u03b1) can reverse the underlying Th2-driven immune response and has successfully induced remission in previous reports. We undertook this study to investigate its efficacy and safety in patients with EGPA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>We conducted a retrospective monocentric cohort study including 30 patients (16 women) with active EGPA under IFN-\u03b1 treatment. Primary endpoints were remission induction, occurrence of relapses, prednisolone (PSL) dosage at time of remission, and adverse events. Remission was defined by a Birmingham Vasculitis Activity Score (BVAS) of 0. Pulmonary function tests were recorded at baseline and at time of remission. Health-related quality of life was analyzed by questionnaire at baseline and following 12 months of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>At baseline, the median BVAS was 6 (interquartile range 4\u201313.5) and remission or partial response was achieved in 25\/30 patients. After initiation of IFN-\u03b1 treatment, the median PSL dosages could be reduced from 17.5 mg\/day at baseline to 5.5 mg\/day at time of remission. Following remission, 17 relapses (5 major) in 16 patients were observed. Pulmonary function tests improved and the time of hospitalization decreased. Adverse events at initiation of treatment were common, but mostly transient. Severe adverse events occurred during treatment in 4 patients (autoimmune hepatitis, n = 1; drug-induced neuropathy, n = 3).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>IFN-\u03b1 treatment results in high rate of remission and maintenance in EGPA with significant reduction in oral corticosteroids, although reversible adverse events may occur. IFN-\u03b1 represents an alternative therapeutic option in cases of refractory to standard treatment.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.160907","type":"journal-article","created":{"date-parts":[[2017,4,16]],"date-time":"2017-04-16T00:10:12Z","timestamp":1492301412000},"page":"806-814","source":"Crossref","is-referenced-by-count":21,"title":["Interferon-\u03b1 for Induction and Maintenance of Remission in Eosinophilic Granulomatosis with Polyangiitis: A Single-center Retrospective Observational Cohort Study"],"prefix":"10.3899","volume":"44","author":[{"given":"Benjamin","family":"Seeliger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"F\u00f6rster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janett","family":"Happe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Forberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Moeser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Kroegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2017,4,15]]},"reference":[{"key":"2018112909370434000_44.6.806.1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37715"},{"key":"2018112909370434000_44.6.806.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.37721"},{"key":"2018112909370434000_44.6.806.3","first-page":"277","article-title":"Allergic granulomatosis, allergic angiitis, and periarteritis nodosa","volume":"27","author":"Churg","year":"1951","journal-title":"Am J Pathol"},{"key":"2018112909370434000_44.6.806.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101279"},{"key":"2018112909370434000_44.6.806.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.23198"},{"key":"2018112909370434000_44.6.806.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.22679"},{"key":"2018112909370434000_44.6.806.7","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199601000-00003"},{"key":"2018112909370434000_44.6.806.8","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000015"},{"key":"2018112909370434000_44.6.806.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209133"},{"key":"2018112909370434000_44.6.806.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2015.04.022"},{"key":"2018112909370434000_44.6.806.11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes171"},{"key":"2018112909370434000_44.6.806.12","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200102)44:2<469::AID-ANR66>3.0.CO;2-0"},{"key":"2018112909370434000_44.6.806.13","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2000.00720.x"},{"key":"2018112909370434000_44.6.806.14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-267542"},{"key":"2018112909370434000_44.6.806.15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118417"},{"key":"2018112909370434000_44.6.806.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.03.016"},{"key":"2018112909370434000_44.6.806.17","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2003.02128.x"},{"key":"2018112909370434000_44.6.806.18","first-page":"60","article-title":"Interferon-\u03b1 induced remission in three patients with eosinophilic granulomatosis and polyangiitis. A case study","volume":"10","author":"Seeliger","year":"2013","journal-title":"Respir Med Case Rep"},{"key":"2018112909370434000_44.6.806.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0953-6205(02)00136-X"},{"key":"2018112909370434000_44.6.806.20","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1055\/s-2003-40284","article-title":"[Interferon-alpha treatment of the Churg-Strauss syndrome]","volume":"128","author":"Reissig","year":"2003","journal-title":"Dtsch Med Wochenschr"},{"key":"2018112909370434000_44.6.806.21","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-129-5-199809010-00004"},{"issue":"Suppl 49","key":"2018112909370434000_44.6.806.22","first-page":"S35","article-title":"A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome","volume":"26","author":"Metzler","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909370434000_44.6.806.23","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1214738"},{"key":"2018112909370434000_44.6.806.24","doi-asserted-by":"publisher","DOI":"10.1159\/000088660"},{"issue":"Suppl 57","key":"2018112909370434000_44.6.806.25","first-page":"24","article-title":"Interferon-alpha for maintenance of remission in Churg-Strauss syndrome: a long-term observational study","volume":"28","author":"Metzler","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909370434000_44.6.806.26","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"2018112909370434000_44.6.806.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.09.022"},{"key":"2018112909370434000_44.6.806.28","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330806"},{"key":"2018112909370434000_44.6.806.29","first-page":"31","article-title":"Development and validation of a disease extent index for Wegener\u2019s granulomatosis","volume":"55","author":"de Groot","year":"2001","journal-title":"Clin Nephrol"},{"key":"2018112909370434000_44.6.806.30","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.062711"},{"key":"2018112909370434000_44.6.806.31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206095"},{"key":"2018112909370434000_44.6.806.32","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1002\/art.39663","article-title":"Anti-IgE monoclonal antibody (Omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss): data on seventeen patients","volume":"68","author":"Jachiet","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2018112909370434000_44.6.806.33","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-155-5-201109060-00026"},{"key":"2018112909370434000_44.6.806.34","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.7.1342"},{"key":"2018112909370434000_44.6.806.35","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0106"},{"key":"2018112909370434000_44.6.806.36","doi-asserted-by":"publisher","DOI":"10.1089\/107999001300177457"},{"key":"2018112909370434000_44.6.806.37","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31825d9982"},{"key":"2018112909370434000_44.6.806.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.03.028"},{"key":"2018112909370434000_44.6.806.39","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201531"},{"key":"2018112909370434000_44.6.806.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2013.03.003"},{"key":"2018112909370434000_44.6.806.41","doi-asserted-by":"publisher","DOI":"10.1046\/j.1398-9995.2003.00424.x"},{"key":"2018112909370434000_44.6.806.42","doi-asserted-by":"publisher","DOI":"10.3109\/02770903.2010.551796"},{"key":"2018112909370434000_44.6.806.43","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3109\/02770903.2015.1081700","article-title":"Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study","volume":"53","author":"Detoraki","year":"2016","journal-title":"J Asthma"},{"key":"2018112909370434000_44.6.806.44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2008.01854.x"},{"key":"2018112909370434000_44.6.806.45","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20176"},{"key":"2018112909370434000_44.6.806.46","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1279831"},{"key":"2018112909370434000_44.6.806.47","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfu406"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.160907","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T19:20:48Z","timestamp":1543519248000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.160907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,15]]},"references-count":47,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6,1]]},"published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.3899\/jrheum.160907"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.160907","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,15]]}}}